Equities Analysts Offer Predictions for FDMT Q1 Earnings

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of 4D Molecular Therapeutics in a report issued on Monday, March 3rd. HC Wainwright analyst M. Caufield anticipates that the company will earn ($0.92) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $36.00 target price on the stock. The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.84) per share. HC Wainwright also issued estimates for 4D Molecular Therapeutics’ Q2 2025 earnings at ($0.93) EPS, Q3 2025 earnings at ($0.93) EPS, Q4 2025 earnings at ($0.94) EPS, FY2025 earnings at ($3.72) EPS, FY2026 earnings at ($4.00) EPS, FY2027 earnings at ($4.32) EPS, FY2028 earnings at ($4.07) EPS and FY2029 earnings at ($2.80) EPS.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings data on Friday, February 28th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.10).

Other research analysts also recently issued reports about the stock. Morgan Stanley lowered their price objective on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating for the company in a research report on Monday, January 13th. Leerink Partners lowered their price target on 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating for the company in a report on Monday, January 13th. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Friday. Bank of America decreased their target price on 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Finally, BMO Capital Markets cut shares of 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $40.00 to $15.00 in a report on Monday, January 13th. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $31.38.

4D Molecular Therapeutics Trading Down 1.7 %

Shares of 4D Molecular Therapeutics stock opened at $4.07 on Thursday. The company has a market cap of $188.45 million, a PE ratio of -1.43 and a beta of 2.83. The company has a 50 day moving average of $5.08 and a 200-day moving average of $8.34. 4D Molecular Therapeutics has a 1-year low of $3.92 and a 1-year high of $36.25.

Institutional Trading of 4D Molecular Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Decheng Capital LLC boosted its position in 4D Molecular Therapeutics by 0.5% during the 4th quarter. Decheng Capital LLC now owns 400,000 shares of the company’s stock worth $2,228,000 after buying an additional 2,165 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in 4D Molecular Therapeutics by 7.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 44,324 shares of the company’s stock valued at $247,000 after acquiring an additional 2,925 shares during the period. PNC Financial Services Group Inc. raised its stake in shares of 4D Molecular Therapeutics by 66.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock valued at $51,000 after acquiring an additional 3,630 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of 4D Molecular Therapeutics by 5.3% during the fourth quarter. Rhumbline Advisers now owns 73,431 shares of the company’s stock worth $409,000 after purchasing an additional 3,675 shares during the period. Finally, ProShare Advisors LLC increased its holdings in 4D Molecular Therapeutics by 30.1% in the fourth quarter. ProShare Advisors LLC now owns 16,369 shares of the company’s stock valued at $91,000 after purchasing an additional 3,783 shares during the period. 99.27% of the stock is currently owned by institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.